We are excited to share the New Lancet Oncology Commission on Future Research Priorities in the USA sets out how to accelerate cancer research and care, delivering on US Cancer Moonshot initiative. The report builds on the Blue Ribbon Panel recommendations and is authored by over 50 leading oncologists in the USA. The report sets out 13 key priority areas to achieve 10 years of progress within 5 years. Explore all of the report’s recommendations: www.thelancet-oncology.com/usa-commission
We are especially proud that our Executive Director, Ruth Hoffman, is one of the Commissioners for the Pediatric Section. Please watch the video and find more details below.
- Drug Discovery & Development: Hundreds of drugs fail in clinical trials – how can we improve drug development?
- Cancer Prevention: One-size-fits-all approach is not suitable – need precision therapy + prevention.
- Paediatric Oncology: We must strive to cure more children + inflict less harm: priorities in pediatrics.
- Surgical Oncology: Surgery is the cornerstone of potentially curative therapy for solid malignancies.
- Health Disparities and Access to Care: Addressing health disparities in cancer care – important across all recommendations.
- Data Sharing and Big Data Analysis: Big data is redefining science +management of #cancer.
- Supportive Oncology: 15.5 million Americans are cancer survivors – supportive care is a key priority.
- Immunotherapy: the rising star of cancer treatment: key research priority.
About the Commission:
The Lancet Oncology Commission on Future Research Priorities in the USA is authored by over 50 leading oncologists in the USA, including members of leading US cancer organizations, and sets out 13 key priority areas, each with measurable goals, to focus the US$2 billion of funding released to the National Cancer Institute as part of the 21st Century Cures Act.
The report builds on the Blue Ribbon Panel recommendations and sets out a detailed roadmap to accelerate cancer research. Priorities include a focus on prevention, a new model for drug discovery and development, a vast expansion of patient access to clinical trials, and an emphasis on targeted interventions to improve cancer care for underserved groups, specifically children, cancer survivors and minority groups. The report emphasizes the importance of addressing health disparities in all recommendations.
It highlights how technological advances, including understanding and mapping pre-cancer biology and the rapid adoption of big data, as well as new collaborations across industry, patient groups, academia, government and clinical practice, will be critical to advancing research, and ultimately improving patient care.
The Commission will be launched on November 1st at an event on Capitol Hill, Washington, DC and presented on November 3rd at the United Nations Association of New York Humanitarian Awards, where former Vice President Joe Biden is being honored for his work on improving cancer outcomes as part of the US Cancer Moonshot Initiative.